Vapotherm, Inc. (NYSE:VAPO – Get Rating) Director James W. Liken bought 20,000 shares of the business's stock in a transaction that occurred on Thursday, August 18th. The stock was acquired at an average cost of $1.70 per share, with a total value of $34,000.00. Following the completion of the acquisition, the director now owns 154,378 shares of the company's stock, valued at approximately $262,442.60. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Vapotherm Stock Down 6.6 %
NYSE:VAPO opened at $1.55 on Tuesday. Vapotherm, Inc. has a twelve month low of $1.49 and a twelve month high of $31.87. The company has a market cap of $41.38 million, a price-to-earnings ratio of -0.42 and a beta of -0.22. The stock has a fifty day simple moving average of $2.24 and a 200-day simple moving average of $6.75. The company has a current ratio of 5.29, a quick ratio of 3.25 and a debt-to-equity ratio of 7.04.
Get
Vapotherm alerts:
Vapotherm (NYSE:VAPO – Get Rating) last released its earnings results on Wednesday, August 3rd. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.06). Vapotherm had a negative return on equity of 142.53% and a negative net margin of 102.94%. The business had revenue of $12.97 million for the quarter, compared to the consensus estimate of $19.34 million. Analysts anticipate that Vapotherm, Inc. will post -2.87 EPS for the current year.
Analyst Ratings Changes
VAPO has been the subject of a number of recent research reports. Canaccord Genuity Group lowered shares of Vapotherm from a "buy" rating to a "hold" rating and cut their target price for the company from $12.00 to $5.00 in a report on Friday, May 6th. Piper Sandler dropped their price objective on shares of Vapotherm from $2.50 to $2.00 and set an "underweight" rating for the company in a research note on Thursday, August 4th. BTIG Research lowered shares of Vapotherm from a "buy" rating to a "neutral" rating in a research note on Thursday, August 4th. Canaccord Genuity Group lowered shares of Vapotherm from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $12.00 to $5.00 in a research note on Friday, May 6th. Finally, William Blair lowered shares of Vapotherm from an "outperform" rating to a "market perform" rating in a research note on Thursday, August 4th. One research analyst has rated the stock with a sell rating and four have issued a hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $4.75.
Institutional Trading of Vapotherm
Several institutional investors and hedge funds have recently made changes to their positions in the company. Prescott General Partners LLC raised its holdings in shares of Vapotherm by 45.0% in the first quarter. Prescott General Partners LLC now owns 2,557,243 shares of the company's stock valued at $35,546,000 after acquiring an additional 793,504 shares in the last quarter. Crow s Nest Holdings LP raised its holdings in shares of Vapotherm by 5.6% in the second quarter. Crow s Nest Holdings LP now owns 1,630,876 shares of the company's stock valued at $4,126,000 after acquiring an additional 86,026 shares in the last quarter. Hound Partners LLC raised its holdings in shares of Vapotherm by 2.7% in the fourth quarter. Hound Partners LLC now owns 1,402,987 shares of the company's stock valued at $29,056,000 after acquiring an additional 37,135 shares in the last quarter. Parian Global Management LP raised its holdings in Vapotherm by 3.0% in the second quarter. Parian Global Management LP now owns 1,368,575 shares of the company's stock worth $3,462,000 after purchasing an additional 40,466 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in Vapotherm by 1,598.6% in the second quarter. Millennium Management LLC now owns 985,992 shares of the company's stock worth $2,495,000 after purchasing an additional 927,944 shares in the last quarter. 69.67% of the stock is currently owned by institutional investors.
About Vapotherm
(Get Rating)
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
See Also
- Get a free copy of the StockNews.com research report on Vapotherm (VAPO)
- MarketBeat Podcast: Fantasy Football Strategy With Your Stock Portfolio
- Should You Buy These Copper Stocks Ahead Of Monster Demand?
- Three Industrial Stocks That Can Weather a Stormy Recession
- Bed Bath & Beyond Meat: Is BYND the Next Big Short Squeeze?
- Denbury Rises On Rumor Of A Sale, But Lags Other Energy Names
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.
